NCT02778152 is a NA clinical trial of Laser depilation in Pilonidal Disease, sponsored by Peter Minneci.

Who is sponsoring NCT02778152?

NCT02778152 is sponsored by Peter Minneci.

What drugs are being tested in NCT02778152?

Interventions in NCT02778152: Laser depilation.

What condition does NCT02778152 study?

NCT02778152 studies Pilonidal Disease.

Is NCT02778152 still recruiting?

NCT02778152 is currently completed. Last updated 26 March 2019.

Are results published for NCT02778152?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2019-03-26 · How we verify

NCT02778152

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pilot Study of Laser Hair Depilation for Pilonidal Disease

Completed NA Results posted Last updated 26 March 2019

What this trial tests

NA trial testing Laser depilation in Pilonidal Disease in 13 participants. Completed in 2 February 2018.

Timeline

19 February 2016

Primary endpoint
2 February 2018

2 February 2018

Quick facts

Lead sponsor	Peter Minneci
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	13
Start date	19 February 2016
Primary completion	2 February 2018
Estimated completion	2 February 2018
Sites	1 location across United States

Drugs / interventions tested

Laser depilation

Conditions studied

Pilonidal Disease — all drugs for Pilonidal Disease →

Sponsor

Peter Minneci — full company profile →

Who can join

Adults 12 to 20, any sex, with Pilonidal Disease. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Tolerability of Laser Treatment Primary · five months

Median of pain scores immediately post-laser treatment after each of the 5 treatments. Pain was assessed on a scale of 1 to 10, 10 being the greatest amount of pain.

Group	Value	95% CI
Laser Group	2	2 – 2

Number of Participants Experiencing Second Degree Burns Post-Treatment Secondary · five months

Incidence of skin burn within the first 48 hours after each of the 5 treatments

Group	Value	95% CI
Laser Group	0

Sponsor's own description

Pilot study to assess tolerability and safety of laser hair depilation in adolescents and young adults with pilonidal disease.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Laser depilation

Trials testing the same drug.

NCT03276065 — Effectiveness of Laser Hair Removal in Pilonidal Disease · NA · unknown

Other recruiting trials for Pilonidal Disease

Currently open trials in the same condition.

NCT07321704 — Effect of Antiseptic Irrigations With 0.05% Chlorhexidine Gluconate (Irrisept) Versus Normal Saline on Fasciocutaneous F · NA · recruiting
NCT06406621 — Pilot Trial Assessing the Effectiveness of Laser Hair Depilation on Pilonidal Disease Recurrence in Patients With Darker · NA · recruiting
NCT06286397 — Topical Anti-Androgens in Pilonidal Sinus Disease · Phase 2 · recruiting
NCT06391307 — The Role of Mesenchymal Stem Cell and Exosome in Treating Pilonidal Sinus Disease in Children · NA · recruiting
NCT03772873 — MIPE for Pilonidal Disease · active not recruiting

Other Peter Minneci trials

Trials by the same sponsor.

NCT02110485 — Randomized Controlled Trial of a Patient Activation Tool in Pediatric Appendicitis (Antibiotics Alone vs. Appendectomy) · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02778152 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Peter Minneci
Last refreshed: 26 March 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02778152.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing